DRI Healthcare Trust (TSE:DHT.UN) Given Consensus Rating of “Moderate Buy” by Brokerages

DRI Healthcare Trust (TSE:DHT.UN) has been given an average rating of “Moderate Buy” by the seven brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is C$18.25.

DHT.UN has been the subject of a number of analyst reports. Scotiabank increased their price target on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Truist Financial reduced their target price on DRI Healthcare Trust from C$17.00 to C$14.00 in a research note on Thursday, July 25th.

DRI Healthcare Trust Price Performance

DRI Healthcare Trust stock opened at C$13.25 on Friday. DRI Healthcare Trust has a one year low of C$10.39 and a one year high of C$17.43. The stock’s 50 day moving average price is C$13.15 and its 200 day moving average price is C$13.75.

DRI Healthcare Trust Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 18th. Shareholders of record on Friday, October 18th were paid a $0.085 dividend. The ex-dividend date was Friday, September 27th. This represents a $0.34 annualized dividend and a dividend yield of 2.57%. DRI Healthcare Trust’s payout ratio is currently -920.00%.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.